Moderna announced study showing Its COVID-19 vaccine maintained antibodies against variants of concern
On Aug. 12, 2021, Moderna announced the publication of new data on the durability of the Moderna COVID-19…
Innovation Pharmaceuticals’ phase 2 clinical trial of Brilacidin for COVID-19 trial database under review in preparation for lock
On Aug. 12, 2021, Innovation Pharma released information regarding the status of its randomized, double-blind, placebo-controlled Phase 2…
NIH launched study of third COVID-19 vaccine dose in kidney transplant recipients
On Aug. 10, 2021, the National Institutes of Health (NIH) announced that a pilot study had begun to…
Moderna and Canada announced collaboration to bring mRNA manufacturing to Canada
On Aug. 10, 2021, Moderna announced a Memorandum of Understanding (MoU) with the government of Canada to build…
Australian Therapeutic Goods Administration granted provisional registration for Moderna’s COVID-19 vaccine
On Aug. 9, 2021, Moderna announced that the Therapeutic Goods Administration (TGA) had granted provisional registration to the…
INOVIO and Advaccine receive regulatory allowance for prime-boost clinical trials in China using INO-4800, COVID-19 DNA vaccine candidate
On Aug. 9, 2021, Inovio Pharma announced that it had received regulatory allowance for two clinical trials investigating…
Novavax announced COVID-19 vaccine booster data demonstrating four-fold Increase in neutralizing antibody
On Aug. 5, 2021, Novavax announced preliminary data demonstrating that a single booster dose of its recombinant nanoparticle…
Novavax and EC finalized advance purchase agreement for up to 200 million doses of COVID-19 vaccine
On Aug. 4, 2021, Novavax announced that it had reached an agreement with the European Commission (EC) for…
Moderna received FDA Fast Track Designation for Respiratory Syncytial Virus vaccine
On Aug. 3, 2021, Moderna announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track…
CytoDyn received clearance from Brazil’s FDA (ANVISA) to commence pivotal phase 3 trial in critically ill COVID-19 patients
On Aug. 3, 2021, CytoDyn announced that Brazil’s regulatory authority ANVISA (Agência Nacional de Vigilância Sanitária) has approved…
Vaxart reported boosting immune responses in subjects previously vaccinated by a Vaxart vaccine
On Jul. 29, 2021, Vaxart announced that it has shown for the first time in clinical trials that…
Second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrated improved immune response and protection in preclinical study
On Jul. 28, 2021, GlaxoSmithKline and Vir Biotechnology announced they had signed a Joint Procurement Agreement with the…
Oragenics entered into licensing agreement with the NRC of Canada, to pursue next-generation SARS-CoV-2 vaccines
On Jul. 27, 2021, Oragenics announced it had entered into a licensing agreement with the National Research Council…
CHMP adopted positive opinion recommending authorization for use of the Moderna COVID-19 vaccine in adolescents in EU
On Jul. 23, 2021, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
Moderna announced agreement with Taiwan for 20 million doses of Moderna’s COVID-19 Vaccine and variant booster
On Jul. 22, 2021, Moderna announced a new supply agreement with Taiwan for 20 million doses of Moderna’s…
Moderna partnered with Takeda and Government of Japan to aupply additional 50 million doses of COVID-19 vaccine and variant booster candidate
On Jul. 20, 2021, Moderna announced that the Ministry of Health, Labour and Welfare of Japan (MHLW) and…
Moderna announced supply agreement with Argentina for 20 million doses of its COVID-19 vaccine
On Jul. 12, 2021, Moderna announced a supply agreement with the government of Argentina for 20 million doses…
Moderna announced Recipharm site in France manufacturing COVID-19 Vaccine following approval by EMA
On Jul. 1, 2021, Moderna confirmed that following the European Medicines Agency’s (EMA) Committee for Human Medicines (CHMP)…
Novavax published results of UK phase 3 clinical trial demonstrating high levels of COVID-19 vaccine efficacy
On Jun. 30, 2021, Novavax announced the publication of results from the final analysis of a pivotal Phase…
Paratek announced first BARDA Project BioShield procurement of NUZYRA (omadacycline)
On Jun. 29, 2021, Paratek Pharmaceuticals announced it had delivered the first procurement of NUZYRA to the Biomedical…
Moderna provides a clinical update on neutralizing activity of COVID-19 vaccine on emerging variants
On Jun. 29, 2021, Moderna announced new results from in vitro neutralization studies of sera from individuals vaccinated…
Moderna announces Emergency Use Authorization for its COVID-19 vaccine granted by Government of India
On Jun. 29, 2021, Moderna announced that the government of India had issued a registration certificate and a…
European Commission purchased additional 150 million doses of Moderna’s COVID-19 vaccine for delivery in 2022
On Jun. 22, 2021, Moderna announced that the European Commission (EC) had purchased an additional 150 million doses…
U.S. Government purchased additional 200 million doses of Moderna’s COVID-19 vaccine
On Jun. 16, 2021, Moderna announced that the U.S. government had purchased an additional 200 million doses of…
KPWHRI announced volunteers needed for COVID-19 vaccine-booster trial
On Jun. 16, 2021, Kaiser Permanente Washington Health Research Institute (KPWHRI) announced that was recruiting volunteers in the…
Moderna and Magenta partner to distribute Moderna’s COVID-19 vaccine in United Arab Emirates
On Jun. 15, 2021, Moderna and Magenta Investments, an industrial conglomerate in the United Arab Emirates (UAE), announced…
Moderna submitted authorization application for its COVID-19 vaccine in adolescents in Switzerland
On Jun. 14, 2021, Moderna announced that it had submitted an authorization application to Swissmedic for use of…
Novavax COVID-19 vaccine demonstrated 90% overall efficacy and 100% protection in phase 3 trial
On Jun. 14, 2021, Novavax announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against…
Novavax announced positive results from study of influenza vaccine and COVID-19 vaccine candidate administered simultaneously
On Jun. 14, 2021, Novavax announced data from the first co-administration study of a SARS-CoV-2 vaccine candidate [Novavax,…
Novavax announces positive data from three complementary studies of COVID-19 Beta variant strain vaccine
On Jun. 11, 2021, Novavax announced preclinical and clinical data on the company’s original recombinant protein COVID-19 vaccine…